Lepu Medical: The first subject in the Phase II clinical trial of MWN105 injection has been dosed.

Lepu Medical announced that its holding subsidiary, Shanghai Minwei Biotechnology Co., Ltd., has independently developed the innovative drug MWN105 injection for the treatment of overweight or obesity, which is currently undergoing Phase II clinical trials. Recently, the first subject has successfully completed the first dose administration.